Intravenous Ascorbic Acid Administration in Hysterectomy
Effect of Ascorbic Acid Administration on Intraoperative Blood Loss and Wound Healing in Total Abdominal Hysterectomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of
- Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- To be 18 years and older
- No smoking
- No history of bleeding disorder
- No history of favism
- No history of uterus, ovary, cervical cancer
Exclusion Criteria:
- Need to injection of vasopressor drugs
- Surgeon disagreement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: vitamin C
Intervention patients will be received double dose of Ascorbic acid via intravenous injection
|
water-soluble vitamin C injection contain of 1000 mg vitamin C that given via intravenous injection
Other Names:
|
|
No Intervention: Control
Control patients will not be received any intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
volume of hemorrhage
Time Frame: During surgery
|
volume of hemorrhage during surgery
|
During surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hemoglobin value
Time Frame: 6 and 24 hours after surgery
|
Hemoglobin value after surgery
|
6 and 24 hours after surgery
|
|
wound healing
Time Frame: during 2 weeks post surgery
|
complications after surgery
|
during 2 weeks post surgery
|
|
duration of stay in hospital
Time Frame: up to 2 weeks post surgery
|
Length of stay in hospital
|
up to 2 weeks post surgery
|
|
Infection
Time Frame: up to 2 weeks post surgery
|
Developing infection up to 2 weeks
|
up to 2 weeks post surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: zahra vahdat shariatpanahi, MD,PhD, Associatec professor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 17912
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.